|
1
|
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
|
Blood
|
2000
|
2.48
|
|
2
|
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
|
Blood
|
2000
|
1.81
|
|
3
|
Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C.
|
J Biol Chem
|
1993
|
1.51
|
|
4
|
Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia.
|
Leukemia
|
2006
|
1.24
|
|
5
|
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia.
|
Leukemia
|
2002
|
1.07
|
|
6
|
Neoplastic heart disease -- the Muenster experience with 108 patients.
|
Thorac Cardiovasc Surg
|
2005
|
1.04
|
|
7
|
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
|
Ann Oncol
|
2011
|
0.98
|
|
8
|
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia.
|
Leukemia
|
2007
|
0.95
|
|
9
|
Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis.
|
Ann Oncol
|
2008
|
0.94
|
|
10
|
Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity.
|
Leukemia
|
2007
|
0.93
|
|
11
|
Stable remission after administration of rituximab in a patient with primary hepatic marginal zone B-cell lymphoma.
|
Eur J Haematol
|
2005
|
0.86
|
|
12
|
Chemotherapy in metastatic malignant triton tumor: report on two cases.
|
Oncol Rep
|
2007
|
0.84
|
|
13
|
Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study.
|
Eur Radiol
|
2014
|
0.83
|
|
14
|
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries.
|
Atherosclerosis
|
1999
|
0.81
|
|
15
|
[Primary Burkitt lymphoma of the heart--diagnosis and therapy].
|
Z Kardiol
|
2002
|
0.81
|
|
16
|
Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment.
|
Eur Respir J
|
2009
|
0.80
|
|
17
|
Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants.
|
Cardiovasc Res
|
1997
|
0.78
|
|
18
|
Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy.
|
Br J Haematol
|
1994
|
0.78
|
|
19
|
Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients.
|
J Infect Dis
|
1997
|
0.77
|
|
20
|
Subgroup specific therapy effects in AML: AMLCG data.
|
Ann Hematol
|
2004
|
0.76
|
|
21
|
Acquired haemophilia in a patient with gram-negative urosepsis and bladder cancer.
|
Haemophilia
|
2005
|
0.75
|
|
22
|
Thalidomide for the treatment of acute myeloid leukemia.
|
Leuk Lymphoma
|
2003
|
0.75
|
|
23
|
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
|
Leuk Res
|
2007
|
0.75
|
|
24
|
[Not Available].
|
Z Kardiol
|
2002
|
0.75
|
|
25
|
Matrix metalloproteinase/integrin interactions as target for anti-angiogenic treatment strategies.
|
Ann Hematol
|
2002
|
0.75
|
|
26
|
High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.
|
Bone Marrow Transplant
|
2012
|
0.75
|